ERGO (Entia Biosciences) FCF Margin %: -956.52% (As of Dec. 2016)


What is Entia Biosciences FCF Margin %?

Entia Biosciences ERGO FCF Margin % is -956.52% as of Dec. 2016.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Entia Biosciences's Free Cash Flow for the three months ended in Dec. 2016 was $-0.44 Mil. Entia Biosciences's Revenue for the three months ended in Dec. 2016 was $0.05 Mil. Therefore, Entia Biosciences's FCF Margin % for the quarter that ended in Dec. 2016 was -956.52%.

As of today, Entia Biosciences's current FCF Yield % is 0.00%.

The historical rank and industry rank for Entia Biosciences's FCF Margin % or its related term are showing as below:

ERGO' s FCF Margin % Range Over the Past 10 Years
Min: -272.83   Med: 0   Max: 0
Current: -272.83

ERGO's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -85.21 vs ERGO: -272.83

Entia Biosciences FCF Margin % Related Terms

Entia Biosciences FCF Margin % Historical Data

* Premium members only.

The historical data trend for Entia Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entia Biosciences FCF Margin % Chart

Entia Biosciences Annual Data
Trend Jul07 Jul08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -102.44 -264.13 -110.52 -160.81 -272.45

Entia Biosciences Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.24 -131.65 -107.14 -176.19 -956.52

ERGO vs OBMP, NSPX, ATRX: FCF Margin % Comparison

For the Biotechnology subindustry, Entia Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entia Biosciences FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entia Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Entia Biosciences's FCF Margin % falls into.


Entia Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Entia Biosciences's FCF Margin for the fiscal year that ended in Dec. 2016 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2016 )/Revenue (A: Dec. 2016 )
=-0.722/0.265
=-272.45 %

Entia Biosciences's FCF Margin for the quarter that ended in Dec. 2016 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2016 )/Revenue (Q: Dec. 2016 )
=-0.44/0.046
=-956.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -956.52% mean?
Entia Biosciences (ERGO) has a FCF Margin % of -956.52% as of Dec. 2016. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Entia Biosciences and its competitors.
Is Entia Biosciences' FCF Margin % too high?
Entia Biosciences' current FCF Margin % is -956.52%.
How does Entia Biosciences' FCF Margin % compare to OBMP and NSPX?
Entia Biosciences' FCF Margin % of -956.52% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Entia Biosciences and its competitors. Entia Biosciences's current FCF Margin % is -956.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current FCF Margin % of -956.52%. The current FCF Margin % is -956.52%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current FCF Margin % is -956.52% as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entia Biosciences Business Description

Address 13565 South West Tualatin-Sherwood Road, Suite 800, Sherwood, OR, USA, 97140
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.